Shixue Yang

Chongqing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

LPC-engineered liposomes activate transcytosis for paclitaxel brain delivery and potentiation of TTFields/TMZ via TALECT regimen in glioblastoma.

LPC-engineered liposomes activate transcytosis for paclitaxel brain delivery and potentiation of TTFields/TMZ via TALECT regimen in glioblastoma.

Journal: Theranostics
Published: July 29, 2025

PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization.

PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization.

Journal: Neuro-oncology
Published: May 14, 2025

Endothelial cell-derived SDF-1α elicits stemness traits of glioblastoma via dual-regulation of GLI1.

Endothelial cell-derived SDF-1α elicits stemness traits of glioblastoma via dual-regulation of GLI1.

Journal: Theranostics
Published: December 15, 2024

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways.

Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways.

Journal: Cancer biology & medicine
Published: November 27, 2024

Transition Layer Assisted Synthesis of Defect Free Amine-Phosphine Based InP QDs.

Transition Layer Assisted Synthesis of Defect Free Amine-Phosphine Based InP QDs.

Journal: Nano letters
Published: July 11, 2024

Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma.

Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma.

Journal: Acta pharmaceutica Sinica. B
Published: June 26, 2024

HIF1α/ATF3 partake in PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma.

HIF1α/ATF3 partake in PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma.

Journal: Neuro-oncology
Published: March 05, 2024

CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.

CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.

Journal: Theranostics
Published: November 29, 2023

EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.

EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.

Journal: Cancer letters
Published: October 03, 2023

EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.

EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.

Journal: Neuro-oncology
Published: August 31, 2023

Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma.

Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma.

Journal: CNS neuroscience & therapeutics
Published: August 29, 2023

Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.

Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.

Journal: Cancer communications (London, England)
Published: May 15, 2023
Showing 1-12 of 18

Last Updated: 09/26/2026